Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
2020 · Communications Biology · 161 citations
https://doi.org/10.1038/s42003-020-01441-y
R
Robert T. Jones
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
79
Papers
4.2K
Citations
16
h-index
18
i10-index
Robert T. Jones is an academic researcher from MedStar Franklin Square Medical Center. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Glioma Diagnosis and Treatment & Metal complexes synthesis and properties. The author has an h-index of 16, co-authored 68 publications.
ORCID: 0000-0001-8007-4023Papers by this author
worksMassively parallel sequencing of formalin-fixed paraffin-embedded tissues
2012 · BMC Proceedings · 0 citations
https://doi.org/10.1186/1753-6561-6-s6-p40
Supplementary Tables from NPEPPS Is a Druggable Driver of Platinum Resistance
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25826421
Data from NPEPPS Is a Druggable Driver of Platinum Resistance
2024 · 0 citations
https://doi.org/10.1158/0008-5472.c.7234872.v1
Supplementary Table from NPEPPS Is a Druggable Driver of Platinum Resistance
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25826430.v1
Supplementary Tables from NPEPPS Is a Druggable Driver of Platinum Resistance
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25826424.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat